UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors

Seminars in oncology, 2015-12, Vol.42 (6), p.801-819

2015

Link zum Volltext

Verfügbarkeit prüfen

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11403

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Frontiers in oncology, 2022-01, Vol.11, p.793121-793121

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Cancers, 2024-03, Vol.16 (6), p.1137

2024

Link zum Volltext

Verfügbarkeit prüfen

Late toxicity after radical treatment for locally advanced head and neck cancer

Oral oncology, 2015-08, Vol.51 (8), p.795-799

2015

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002863

2021

Link zum Volltext

Verfügbarkeit prüfen

Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents

Drugs in context, 2020-05, Vol.9

2020

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Clinical cancer research, 2019-08, Vol.25 (16), p.4888-4897

2019

Link zum Volltext

Verfügbarkeit prüfen

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

Cancer discovery, 2022-02, Vol.12 (2), p.402-415

2022

Link zum Volltext

Verfügbarkeit prüfen

The expanding role of immunotherapy

Cancer treatment reviews, 2017-03, Vol.54, p.74-86

2017

Link zum Volltext

Verfügbarkeit prüfen

Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

Clinical cancer research, 2019-06, Vol.25 (11), p.3210-3219

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Clinical cancer research, 2019-05, Vol.25 (9), p.2699-2707

2019

Link zum Volltext

Verfügbarkeit prüfen

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Future oncology (London, England), 2019-04, Vol.15 (10), p.1057-1066

2019

Link zum Volltext

Verfügbarkeit prüfen

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

Clinical cancer research, 2020-04, Vol.26 (8), p.1846-1855

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going

Clinical colorectal cancer, 2022-06, Vol.21 (2), p.71-79

2022

Link zum Volltext

Verfügbarkeit prüfen

High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Clinical cancer research, 2022-01, Vol.28 (1), p.137-149

2022

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints

Targeted oncology, 2016-08, Vol.11 (4), p.469-477

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT121: Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT121-CT121

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.B109-B109

2019

Link zum Volltext

Verfügbarkeit prüfen

Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients

Translational cancer research, 2017-08, Vol.6 (S6), p.S1035-S1039

2017

Link zum Volltext

Verfügbarkeit prüfen

Immuno-Oncology: The Third Paradigm in Early Drug Development

Targeted oncology, 2017-04, Vol.12 (2), p.125-138

2017

Link zum Volltext

Verfügbarkeit prüfen

Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4071-4071

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

European journal of cancer (1990), 2021-09, Vol.155, p.168-178

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(64)
Buchkapitel
(1)

Sprache

Englisch
(65)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Oncology
(23)
Humans
(17)
Female
(12)
Male
(9)
Middle Aged
(9)
Immunotherapy
(8)
Adult
(7)
Aged
(7)
Neoplasms - Drug Therapy
(6)
Tumors
(6)
Chemotherapy
(4)
Medicine
(4)
Medicine & Public Health
(4)
Metastasis
(4)
Molecular Targeted Therapy - Methods
(4)
Patients
(4)
Prognosis
(4)
Cancer
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Late toxicity after radical treatment for locally advanced head and neck cancer

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

The expanding role of immunotherapy

Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints

Abstract CT121: Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients

Immuno-Oncology: The Third Paradigm in Early Drug Development

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

Suchergebnisse filtern